Youcare Pharmaceutical Group's Subsidiary Receives Clinical Trial Approval for YKYY018 Inhalation Solution

Stock News12-02

Youcare Pharmaceutical Group Co.,Ltd. (688658.SH) announced that its wholly-owned subsidiary, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd., has recently received two "Drug Clinical Trial Approval Notices" from the National Medical Products Administration (NMPA). The approvals are for the YKYY018 inhalation solution, intended for post-exposure prophylaxis in individuals in contact with respiratory syncytial virus (RSV) patients and for the treatment of RSV infections. The company will proceed with Phase I clinical trials for this product.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1103090478?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 16:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103090478","market":"hk","top_or_hot":-1,"title":"Youcare Pharmaceutical Group's Subsidiary Receives Clinical Trial Approval for YKYY018 Inhalation Solution","media":"Stock News","content":"<p>Youcare Pharmaceutical Group Co.,Ltd. (688658.SH) announced that its wholly-owned subsidiary, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd., has recently received two \"Drug Clinical Trial Approval Notices\" from the National Medical Products Administration (NMPA). The approvals are for the YKYY018 inhalation solution, intended for post-exposure prophylaxis in individuals in contact with respiratory syncytial virus (RSV) patients and for the treatment of RSV infections. The company will proceed with Phase I clinical trials for this product.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Youcare Pharmaceutical Group's Subsidiary Receives Clinical Trial Approval for YKYY018 Inhalation Solution</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYoucare Pharmaceutical Group's Subsidiary Receives Clinical Trial Approval for YKYY018 Inhalation Solution\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-02 16:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Youcare Pharmaceutical Group Co.,Ltd. (688658.SH) announced that its wholly-owned subsidiary, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd., has recently received two \"Drug Clinical Trial Approval Notices\" from the National Medical Products Administration (NMPA). The approvals are for the YKYY018 inhalation solution, intended for post-exposure prophylaxis in individuals in contact with respiratory syncytial virus (RSV) patients and for the treatment of RSV infections. The company will proceed with Phase I clinical trials for this product.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1103090478","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103090478","pubTimestamp":1764663626,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Youcare Pharmaceutical Group Co.,Ltd. (688658.SH) announced that its wholly-owned subsidiary, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd., has recently received two \"Drug Clinical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688658":"悦康药业","BK0239":"医药制造"},"translate_title":"优康药业集团子公司获得YKYY018吸入溶液临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688658":1},"content_text":"Youcare Pharmaceutical Group Co.,Ltd. (688658.SH) announced that its wholly-owned subsidiary, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd., has recently received two \"Drug Clinical Trial Approval Notices\" from the National Medical Products Administration (NMPA). The approvals are for the YKYY018 inhalation solution, intended for post-exposure prophylaxis in individuals in contact with respiratory syncytial virus (RSV) patients and for the treatment of RSV infections. The company will proceed with Phase I clinical trials for this product.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103090478","isCrawlerRequest":true}